ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2013
LGR5 is a promising biomarker for patients with stage I and II gastric cancer.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Pooled it
- Stem Cell Biomarkers and Tumorigenesis in Gastric Cancer.Journal of personalized medicine · 2022Review
- Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits.Experimental hematology & oncology · 2021Review
- LGR5 expression is associated with prognosis in poorly differentiated gastric adenocarcinoma.BMC cancer · 2021Article
- Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis.Cancer cell international · 2021Review
- Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma - significance of potentially retained stemness.BMC cancer · 2020Article
- The Role of Wnt and R-spondin in the Stomach During Health and Disease.Biomedicines · 2019Review
- Immunohistochemical Analysis of LGR5 and TROY Expression in Gastric Carcinogenesis Demonstrates an Inverse TrendIranian biomedical journal · 2019Article
- The correlation of the expressions of WWOX, LGR5 and vasohibin-1 in epithelial ovarian cancer and their clinical significance.International journal of clinical and experimental pathology · 2019Article
- The Novel Role ofCellular and molecular gastroenterology and hepatology · 2018Article
- Initiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells.Cellular and molecular gastroenterology and hepatology · 2017Review
- RNAi-mediated inhibition of Lgr5 leads to decreased angiogenesis in gastric cancer.Oncotarget · 2017Article
- Clinical significance of putative markers of cancer stem cells in gastric cancer: A retrospective cohort study.Oncotarget · 2016Article
- The adjacent to tumor sample trap.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2016Article
- Lgr5 is a potential prognostic marker in patients with cervical carcinoma.International journal of clinical and experimental pathology · 2015Article
- RKIP inhibits gastric cancer cell survival and invasion by regulating the expression of HMGA2 and OPN.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics.TheScientificWorldJournal · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) expressions in gastric cancer and to evaluate its clinical significance.
methodsLGR5 expression was assessed by immunohistochemistry in 257 gastric cancer patients after surgery. The relationships between LGR5 expression and clinicopathological features and patients prognosis were statistically analyzed.
resultsThe expression of LGR5 was significantly higher in gastric cancers as a cancer stem cell marker than in adjacent normal tissues (P<0.001), and more frequently in patients with intestinal type, well-moderate differentiation and stage I and II (P<0.05). Although we found gastric cancer patients with LGR5 positive expression had a poorer prognosis, it didn't meet statistical significance (P>0.05). LGR5 negative expression was significantly related to the favorable overall survival in stage I and II gastric cancer patients (P<0.05). Furthermore, patients with high LGR5 expression tended to be more likely to get progression and have poorer progress-free survival (P<0.05). Multivariate Cox regression analysis revealed that LGR5 expression was an independent factor of overall survival for the patients with stage I and II gastric cancer (P<0.05).
conclusionsOur results show that LGR5 may play an important role in tumorigenesis and progression and would be a powerful marker to predict the prognosis of patients with stage I and II gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.